Investors’ Patience Is Being Tested Right Now By Cerevel Therapeutics Holdings Inc (NASDAQ: CERE)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Cerevel Therapeutics Holdings Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $41.81 and fluctuated between $41.99 as its day high and $41.75 as its day low. The current market capitalization of Cerevel Therapeutics Holdings Inc is $7.59B. A total of 1.03 million shares were traded on the day, compared to an average of 2.66M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, CERE has seen 6 BUY and 6 SELL insider trades, representing the acquisition of 158,000 and the disposition of 158,000 shares. Over the last 12 months, there were 27 BUYs and 22 SELLs from insiders. Insiders purchased 12,505,204 shares during that period but sold 1,605,279.

In the most recent transaction, COLES N ANTHONY sold 50,000 shares of CERE for 42.24 per share on Jan 02. After the transaction, the Director now owns 2,704 company shares. In a previous transaction on Dec 26, Sanchez Ramiro sold 10,000 shares at 42.47 per share. CERE shares that Chief Medical Officer owns now total 14,673.

Among the insiders who sold shares, DiPietro Kenneth disposed of 8,000 shares on Dec 22 at a per-share price of $41.45. This resulted in the Chief Human Resources Officer holding 24,663 shares of CERE after the transaction. In another insider transaction, ALTSCHULLER Susan sold 13,808 shares at $41.42 per share on Dec 20. Company shares held by the Chief Financial Officer now total 16,913.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, CERE has a high of $42.87 and a low of $19.59.

As of this writing, CERE has an earnings estimate of -$0.6 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$0.65. The company reported an EPS of -$0.63 in the last quarter, which was 3.10% higher than expectations of -$0.65.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CERE’s latest balance sheet shows that the firm has $565.69M in Cash & Short Term Investments as of fiscal 2021. There were $36.55M in debt and $42.54M in liabilities at the time. Its Book Value Per Share was $1.73, while its Total Shareholder’s Equity was $578.73M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CERE is Buy with a score of 3.36.

Most Popular

Related Posts